Related Experiment Video
Updated: Apr 22, 2026
A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer
Published on: July 6, 2017
Designing effective vaccines for colorectal cancer
Sandip P Patel1, Takuya Osada, H Kim Lyerly
1UCSD Moores Cancer Center, Division of Medical Oncology, Cancer Immunotherapy Program, 3855 Health Sciences Drive #0987, La Jolla, CA 92093, USA.
Abstract:
Achieving long-term control of colorectal cancers with therapeutic vaccines that generate potent anti-tumor T cell and antibody responses has been a goal for more than two decades. To date, clinical trials of these vaccines have demonstrated induction of immune responses, but clinical benefit has been limited. Improved vector delivery systems with enhanced immunostimulatory properties, decreased immunogenicity against vector and improved antigen presentation are some of the key features of modern tumor vaccines. Furthermore, an improved understanding of the various immunosuppressive factors in the tumor microenvironment and regional lymph nodes, coupled with a burgeoning ability to impair inhibitory immune synapses, highlights a growing opportunity to induce beneficial antigen-specific responses against tumor. The combination of improved antigenic delivery systems, coupled with therapeutic immune activation, represents state-of-the-art colorectal vaccine design concepts with the goal of augmenting immune responses against tumor and improving clinical outcomes.
Insights
Developing advanced colorectal cancer vaccines aims to boost anti-tumor T cell and antibody responses for better long-term control. Modern vaccine design combines improved delivery systems with immune activation to overcome tumor-induced suppression and enhance clinical outcomes.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Therapeutic vaccines for colorectal cancer have long aimed for durable tumor control.
- Past clinical trials showed immune response induction but limited clinical benefit.
Purpose of the Study:
- To explore advanced colorectal cancer vaccine design strategies.
- To enhance anti-tumor immune responses and improve clinical outcomes.
Main Methods:
- Utilizing improved vector delivery systems with enhanced immunostimulatory properties.
- Optimizing antigen presentation and reducing vector immunogenicity.
- Addressing immunosuppressive factors within the tumor microenvironment and lymph nodes.
Main Results:
- Modern vaccine design focuses on enhanced delivery and immune activation.
- Strategies aim to overcome tumor-induced immune suppression.
- Improved vaccine concepts seek to augment anti-tumor immunity.
Conclusions:
- Combining advanced antigenic delivery with therapeutic immune activation is key.
- This approach represents state-of-the-art colorectal cancer vaccine design.
- The goal is to augment immune responses and improve patient outcomes.
More Related Videos
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:21Vaccines
01:51Vaccinations